Objective:To evaluate the efficacy and toxicity of docetaxel and cisplatin for treatment of hormone independent prostate cancer. Methods:Thirty-two cases hormone independant prostate cancer patients were enrolled in this study. All patients had received castration and/or anti-androgens but relapse with elevated PSA. Multiple metastasis were diagnosed by imaging approach. Before chemotherapy

there were 26 cases suffered from pain by bone metastasis. Docetaxel 75 mg/m2 + NS 250 ml was administered intravenously and cisplatin 100 mg/m2 +NS 500 ml was administered intravenously on the first days. Results:Levels of PSA decreased to normal(<4 ng/ml)in 8 patients

and decreased more than 50 in 13 patients

and did not change in 11 patient.The total effective rate was 65%. After chemotherapy

there were still 17 cases suffered from pain of bone metastasis.The patients were followed-up for 8～49 months(mean time 26.2 months). Of 32 patients

21 patients died from the prostate cancer. The medium survival time was 18.6 months. Average time for remission of pain was 13.9 months. The toxicity of chemotherapy was tolerable

mainly nause

vomiting

leukopenia

decreased hemoglobin and thrombocytopenia. Conclusion:The docetaxel-cisplatin combination regime is effective and tolerable in the treatment for advanced hormone in dependent prostate cancer

it could be considered as one of the adjuvant treatment for advanced hormone independent prostate cancer.